|Articles|March 1, 2004
- BioPharm International-03-01-2004
- Volume 17
- Issue 3
Site Expansion - Regional Roundup: Delaware
Regional Roundup: Delaware
Advertisement
Population (2002)
805,945
Workforce population (2002)
423,200
Unemployment rate (10/02)
4.3%
Key cities and populations
Wilmington: 72,485; Newark: 29,652; Dover: 32,299
Targeted industries
Biotech, agriculture, information technology, tourism, banking and finance, transportation, venture capital
Biopharm employment (2002)
15,224
Academia and government affiliated with biopharm industry
Delaware Technology Park; Delaware Biotech Institute; University of Delaware
Primary business strengths
Extensive pool of scientists and engineers; similar industries based in Delaware; broad regional network of specialized suppliers; one of the lowest costs of doing business regionally
Tax and other incentives
Competitive tax structure, including no state or local general sales tax; no personal property or inventory taxes; real property taxes are among the lowest in the US; corporate income tax credits and reduction of gross receipts taxes for new and expanded businesses; additional tax credits on corporate income and reduction of gross receipt taxes for new and expanding businesses locating in 30 targeted census tracts; property tax relief for new construction and improvements of existing property; the exemption of certain investment and holding companies from corporate income tax; the adherence of the state tax structure to the federal definition of corporate net income so companies may take full advantage of any federal tax law change, such as more rapid depreciation of newly purchased assets. Also, two approved foreign trade zones will allow the deferment of import taxes; Public Utility Tax rebates of 50% on increased consumption for qualifying industries, and reduced rate for manufacturers and agricultural processors. (Visit
BioClusters
Delaware Technology Park:
State committment to biopharm industry growth
Legislative funding; restructuring of Delaware Economic Development Office to clusters one cluster is devoted to life sciences and biotechnology; the state plans to continue to attract new biopharm companies
State- and regional-level contacts
Delaware Economic Development Office, 302.577.8477, Bob Dayton
Articles in this issue
over 21 years ago
Qualifying Release Laboratories in Europe and the United Statesover 21 years ago
Keeping Biopharmaceutical Cleanrooms Compliantover 21 years ago
Tefen Operations Excellenceover 21 years ago
Site Expansion - Regional Roundup: Pennsylvaniaover 21 years ago
Final Word: Beware of Patent Infringement During Discovery Researchover 21 years ago
StreetTalk: It Takes Two (Or Does It?)Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4